Impact of RANK signalling on survival and chemotherapy response in osteosarcoma

Pathology

Volumn 46, Issue 5, 2014, Pages 411-415

  Bago Horvath, Zsuzsanna ^a   Schmid, Katharina ^b   Rössler, Fabian ^a   Nagy Bojarszky, Katalin ^a   Funovics, Philipp ^a   Sulzbacher, Irene ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Chemotherapy response; Osteosarcoma; Prognosis; RANK; RANKL

Indexed keywords

ANTINEOPLASTIC AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; CHILD; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; OSTEOSARCOMA; PHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OSTEOSARCOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84906812780     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000116     Document Type: Article

References (35)

1. Allison DC, Carney SC, Ahlmann ER, et al.Ameta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012; 2012: 704872.
2. Bielack S, Jürgens H, Jundt G, et al. Osteosarcoma: The COSS experience. Cancer Treat Res 2010; 152: 289-308.
3. Bernthal NM, Federman N, Eilber FR, et al. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer 2012; 118: 5888-93.
4. Mankin HJ, Hornicek FJ, Rosenberg AE, et al. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res 2004; 429: 286-91.
5. Chen Y, Yang Y, Yuan Z, et al. Predicting chemosensitivity in osteosarcoma prior to chemotherapy: An investigational study of biomarkers with immunohistochemistry. Oncol Lett 2012; 3: 1011-6.
6. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315-23.
7. Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 1999; 256: 449-55.
8. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999; 96: 3540-5.
9. Goessl C, Katz L, Dougall WC, et al. The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction. Ann NY Acad Sci 2012; 1263: 29-40.
10. Atkins GJ, Bouralexis S, Haynes DR, et al. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone 2001; 28: 370-7.
11. Schramek D, Leibbrandt A, Sigl V, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010; 468: 98-102.
12. Gonzalez-Suarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010; 468: 103-7.
13. Tan W, Zhang W, Strasner A, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011; 470: 548-53.
14. Wittrant Y, Lamoureux F, Mori K, et al. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol 2006; 28: 261-9.
15. Taylor R, Knowles HJ, Athanasou NA. Ewing sarcoma cells express RANKL and support osteoclastogenesis. J Pathol 2011; 225: 195-202.
16. Won KY, Kalil RK, Kim YW, Park YK. RANK signalling in bone lesions with osteoclast-like giant cells. Pathology 2011; 43: 318-21.
17. Gill J, Ahluwalia MK, Geller D, Gorlick R. New targets and approaches in osteosarcoma. Pharmacol Ther 2013; 137: 89-99.
18. Kubista B, Trieb K, Sevelda F, et al. Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res 2006; 24: 1145-52.
19. Dass CR, Choong PF. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol Cancer Ther 2007; 6: 3263-70.
20. Salzer-Kuntschik M, Brand G, Delling G. Determination of the degree of morphological regression following chemotherapy in malignant bone tumors. Pathologe 1983; 4: 135-41.
21. Sulzbacher I, Birner P, Dominkus M, Pichlhofer B, Mazal PR. Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome. Pathology 2010; 42: 664-8.
22. Mori K, Le Goff B, Berreur M, et al. Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J Pathol 2007; 211: 555-62.
23. Zhang W, Lee JC, Kumar S, Gowen M. ERK pathway mediates the activation of Cdk2 in IGF-1-induced proliferation of human osteosarcoma MG-63 cells. J Bone Miner Res 1999; 14: 528-35.
24. Jin S, Shen JN, Wang J, et al. Oridonin induced apoptosis through Akt and MAPKs signaling pathways in human osteosarcoma cells. Cancer Biol Ther 2007; 6: 261-8.
25. Shimo T, Matsumura S, Ibaragi S, et al. Specific inhibitor of MEKmediated cross-talk between ERK and p38 MAPK during differentiation of human osteosarcoma cells. J Cell Commun Signal 2007; 1: 103-11.
26. Beristain AG, Narala SR, Di Grappa MA, Khokha R. Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells. J Cell Sci 2012; 125: 943-55.
27. Na KY, Kim YW, Park YK. Mitogen-activated protein kinase pathway in osteosarcoma. Pathology 2012; 44: 540-6.
28. Lee JA, Jung JS, Kim DH, et al. RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma. Pediatr Blood Cancer 2011; 56: 738-43.
29. Wang Y, Sakata T, Elalieh HZ, et al. Gender differences in the response of CD-1 mouse bone to parathyroid hormone: potential role of IGF-I. J Endocrinol 2006; 189: 279-87.
30. Findlay D, Chehade M, Tsangari H, et al. Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. Arthritis Res Ther 2008; 10: R2.
31. Mori K, Berreur M, Blanchard F, et al. Receptor activator of nuclear factorkappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncol Rep 2007; 18: 1365-71.
32. Lamoureux F, Richard P, Wittrant Y, et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res 2007; 67: 7308-18.
33. Rousseau J, Escriou V, Lamoureux F, et al. Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models. J Bone Miner Res 2011; 26: 2452-62.
34. Salinas-Souza C, De Oliveira R, AlvesMT, et al. The metastatic behavior of osteosarcoma by gene expression and cytogenetic analyses. Hum Pathol 2013; 44: 2188-98.
35. Kaste SC, Liu T, Billups CA, et al. Tumor size as a predictor of outcome in pediatric non- metastatic osteosarcoma of the extremity. Pediatr Blood Cancer 2004; 43: 723-8.